Literature DB >> 34157315

Long non-coding RNAs: A view to kill ovarian cancer.

Alexey V Zamaraev1, Pavel I Volik1, Gennady T Sukhikh2, Gelina S Kopeina3, Boris Zhivotovsky4.   

Abstract

An emerging role of long non-coding RNAs (lncRNAs) in tumor progression has been revealed in the last decade. Through interactions with nucleic acids and proteins, lncRNAs could act as enhancers, scaffolds or decoys for a number of oncoproteins and tumor suppressors. The aberrant lncRNA expression or mutations are often associated with changes in a variety of cellular processes, including proliferation, stress response and cell death. Here, we will focus on the tumor-associated lncRNAs in ovarian cancer according to their contribution to cancer hallmarks, such as intense proliferation, cell death resistance, altered energy metabolism, invasion and metastasis, and immune evasion. Moreover, the potential clinical implications of lncRNAs and their significance for the diagnosis, prognosis and therapy of ovarian cancer will be discussed.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer hallmarks; LncRNAs; Ovarian cancer; Prognosis, targeted therapy

Year:  2021        PMID: 34157315     DOI: 10.1016/j.bbcan.2021.188584

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  3 in total

Review 1.  Role of NRF2 in Ovarian Cancer.

Authors:  Giovanni Tossetta; Sonia Fantone; Eva Montanari; Daniela Marzioni; Gaia Goteri
Journal:  Antioxidants (Basel)       Date:  2022-03-30

Review 2.  The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers.

Authors:  Faiza Naz; Imran Tariq; Sajid Ali; Ahmed Somaida; Eduard Preis; Udo Bakowsky
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

3.  LINC00035 Transcriptional Regulation of SLC16A3 via CEBPB Affects Glycolysis and Cell Apoptosis in Ovarian Cancer.

Authors:  Shuyan Yang; Jing Wang; Rongjie Cheng; Bo Pang; Pengcheng Sun
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-11       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.